Table 3. Summary of F. prausnitzii phylogroups I and II characteristics.
| Phylogroup I | Phylogroup II | |
|---|---|---|
| Strains | ATCC27768, M21/2, S3L/3, S4L/4 | A2-165, L2-6, L2-15, L2-39, L2-61, HTF-A, HTF-B, HTF-C, HTF-E, HTF-F, HTF-I, HTF-75H, HTF-60C |
| Gut distribution | Feces and mucosa | Feces and mucosa |
| Genome size (mean Mb±s.d.)a | 3.17±0.06 | 3.21±0.16 |
| GC content (mean %±s.d.)a | 55.85±0.49 | 56.45±0.21 |
| Genes content (mean±s.d.)a | 2881.5±92.6 | 2892.5±102.5 |
| Proteins content (mean±s.d.)a | 2778.5±46.0 | 2725.5±43.1 |
| Carbohydrate utilization (mean OD650±s.d.)b | ||
| Glucose | 0.750±0.311 | 0.428±0.228 |
| Cellobiose | 0.665±0.277 | 0.383±0.312 |
| Maltose | 0.685±0.247 | 0.603±0.273 |
| Galacturonic acid | 0.373±0.208 | 0.165±0.086 |
| Galactose | 0.435±0.369 | 0.630±0.183 |
| Apple pectin | 0.408±0.108 | 0.270±0.224 |
| Inulin | 0.115±0.065 | 0.510±0.440 |
| Glucuronic acid | 0.150±0.113 | 0.360±0.410 |
| N-Acetylgucosamine | 0.615±0.224 | 0.388±0.369 |
| Glucosamine HCl | 0.345±0.177 | 0.267±0.336 |
| Tolerance to pH (mean growth rate±s.d.)b | ||
| 6.7 | 0.210±0.070 | 0.256±.0151 |
| 6.2 | 0.192±0.050 | 0.245±0.159 |
| 5.75 | 0.081±0.039 | 0.108±0.042 |
| Tolerance to bile salts (mean maximum OD650±s.d.)b | ||
| 0% | 0.717±0.427 | 0.613±0.202 |
| 0.12% | 0.174±0.223 | 0.071±0.150 |
| 0.25% | 0.032±0.037 | 0.014±0.014 |
| 0.5% | 0.026±0.033 | 0.002±0.005 |
| SCFA production (mM ±s.d.)c | ||
| Formate | 3.508±2.730 | 15.190±11.856 |
| Acetate | −8.917±11.288 | −3.192±9.256 |
| Butyrate | 18.524±11.151 | 23.882±5.386 |
| D-Lactate | 2.014±1.992 | 2.435±0.865 |
| Association with host metabolites (adapted from (Li, et al. 2008)) | Decrease in dihydrothymine and an increase in 4-hydroxyphenylacetylglycine | Decreased levels of 3-aminoisobutyrate, taurine, 3, 5-hydroxylbenzoate, dimethylamine, 2-hydroxyisobutyrate, glycolate and increased lactate and glycine |
| Abundance in gut disorders (adapted from (Hippe et al., 2016, Lopez-Siles et al., 2016)) | Depletion in IBS, CRC and IBD patients, particularly in active CD | Depletion in CD patients, especially those with intestinal resection. Associated to type 2 diabetes. |
Abbreviations: CD, Crohn's disease; CRC, colorectal cancer; GC, guanine and cytosine; IBD, inflammatory bowel disease; IBS, irritable bowel syndrome; OD, optical density; SCFA, short chain fatty acids. No statistically significant differences have been found between the members of the two phylogroups for any of the characteristics analyzed.
For these calculations phylogroup I included isolates M21/2 and S3L/3 and phylogroup II consisted of L2/6 and A2-165 isolates.
For these calculations ATCC27768, M21/2, S3L/3 and S4L/4 (phylogroup I) and A2-165, L2-15, L2-39, L2/6, HTF-F and HTF-75H (phylogroup II) were used (Lopez-Siles, et al. 2012).
Short chain fatty acids produced by strains ATCC27768, M21/2, S3L/3 and S4L/4 (phylogroup I) and A2-165 and L2-6 (phylogroup II) on yeast casitone fatty-acids medium supplemented with 0.5% (wt/vol) glucose (Lopez-Siles et al., 2012).